Dr Reddy’s sells US penicillin plant to Abu Dhabi-based Neopharma
Drug maker Dr Reddy’s Laboratories Ltd has sold its antibiotic manufacturing facility in Bristol, US to Abu Dhabi-based pharmaceutical manufacturer Neopharma LLC UAE. The plant and the associated facilities manufactured amoxicillin-based products including a semi-synthetic penicillin. “This sale is in line with our stated priority to streamline and optimize our global cost structures and help us focus on other business priorities to drive growth,” Erez Israeli, chief operating officer at Dr Reddy’s, said in a statement.
With this DRL has also announced the termination of its licence granted to Armis Bio Pharma, Inc (formlychd bioscience, inc) for its investigational antibacterial product, DFA-02, for prophylxis of surgical site infections. Following this DRL has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.